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At odds with long-standing convictions, it is now 
clear that tumors are not immunologically silent entities. 
We have recently demonstrated that the immune system 
can selectively detect and eliminate hyperploid (pre-)
malignant cells, thus delineating a novel mechanism of 
immunosurveillance against tumorigenesis.
Malignant cells of different histological origin 
share a set of common features, including an impressive, 
growth factor-independent proliferative potential as well 
as an increased resistance to potentially lethal stimuli. 
At least in part, such characteristics stem from mutations 
in the genome of (pre-)neoplastic cells that cause either 
the loss-of-function of oncosuppressor genes and/or the 
(hyper)activation of proto-oncogenes [1]. Along with 
tumor progression, newly-formed malignant cells continue 
to accumulate genetic defects that promote a state of 
increased aggressiveness. In some cases, (pre-)malignant 
cells undergo gross chromosomal rearrangements, 
conferring them additional proliferative advantages [2]. 
Although the exact sequence and timing of the molecular 
events that underpin malignant transformation remain 
largely obscure, an elevated degree of genomic instability 
is often associated with enhanced tumor growth and 
aggressiveness. In many instances, genomic instability 
develops along with aneuploidy, a non-diploid state that 
frequently derives from tetraploidy, via multipolar mitosis, 
asymmetric cell division and/or chromosome losses [3]. 
In line with this notion, several cell-intrinsic mechanisms 
are in place to prevent the survival, proliferation or 
replication of illicitly generated tetraploid and aneuploid 
cells, including multiple cell cycle checkpoints and mitotic 
catastrophe [4].
 For decades, tumors have been considered as 
strictly non-immunogenic entities. Such an over-simplistic 
view has been definitively abandoned in the 2000s, along 
with the expanding consensus on Polly Matzinger’s 
“danger theory”. According to this model, the immune 
system does not simply discriminate between self and 
non-self entities but rather reacts to situations of danger, 
irrespective of their origin [5]. In the subsequent years, a 
consistent amount of preclinical and clinical evidence has 
been gathered in support of the notion that malignant cells 
can be recognized and even eliminated by the immune 
system, at least in the initial stages of oncogenesis [6]. 
Thus, also cell-extrinsic barriers to oncogenesis exist, 
most of which are mediated by the immune system. In this 
setting, multiple mechanisms may explain why developing 
malignancies may break immune tolerance (Figure 
1). First, tumor cells often express tumor-associated 
antigens that, at least in some circumstances, are able to 
ignite tumor-specific immune responses. Second, (pre-)
malignant cells frequently upregulate plasma membrane 
receptors that activate cytolytic components of the innate 
immune system such as natural killer (NK) cells [7]. Third, 
neoplastic cells treated with some anticancer therapeutics 
undergo a functionally peculiar type of apoptosis that 
de facto is immunogenic, hence promoting the priming 
of tumor-specific cytotoxic CD8+ cells. Among other 
processes, the immunogenicity of cell death relies on 
the exposure of the endoplasmic reticulum (ER)-sessile 
protein calreticulin (CRT) on cell surface, acting as an 
“eat-me” signal for antigen-presenting cells that ignite a 
cognate immune response [8]. We have recently shown 
that hyperploid cancer cells can also be detected and 
eliminated by the immune system [9], thus delineating 
yet another barrier to tumor progression that operates 
at the interface between cell-intrinsic and cell-extrinsic 
oncosuppressive mechanisms (Figure 1).
As compared to their parental, near-to-diploid 
counterparts, hyperploid cancer cells exhibit a 
constitutively elevated degree of ER stress, manifesting 
with the inactivating phosphorylation of the eukaryotic 
initiation factor 2α (eIF2α) and resulting in increased 
baseline levels of plasma membrane-exposed CRT 
(ecto-CRT) [9]. At least in part owing to higher amounts 
of ecto-CRT, hyperploid cancer cells inoculated into 
immunocompetent hosts form tumors with a reduced 
incidence as compared to their parental counterparts. 
Conversely, near-to-diploid and hyperploid cancer 
cells generate tumors with the same incidence when 
inoculated into immunocompromised mice [9]. Of 
note, hyperploid cell-derived tumors recovered from 
immunocompetent mice exhibit reduced ploidy, lower 
degrees of ER stress and fewer ecto-CRT than xenografts 
generated by the same cells in immunodeficient animals 
[9]. In addition, carcinogen-induced tumors developing 
in immunocompetent mice exhibit reduced ploidy and 
lower degrees of ER than the same lesions developing 
in immunocompromised (Rag2-/- γc-/-, Stat1-/- or Dnam1-
/-) animals [9]. Overall, our observations indicate 
that hyperploidy is a cancer-associated trait that is 
counterselected in vivo by the immune system upon the 
recognition of increased CRT exposure. 
To investigate the translational relevance of our 
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findings, we determined nuclear size (as an indicator of 
ploidy) and eIF2α phosphorylation (as an indicator of 
ER stress) in breast carcinoma biopsies from patients 
who either responded or did not respond to neo-adjuvant 
chemotherapy. In line with previous reports [10], patients 
that underwent clinical responses to chemotherapy 
(responders), but not subjects with detectable lesions in 
spite of six cycles of chemotherapy (non-responders), 
exhibited high amounts of tumor-infiltrating CD8+ T 
cells over immunosuppressive FOXP3+ cells. In addition, 
the few breast carcinoma cells that could be detected in 
responders exhibited a decreased nuclear diameter and 
lower levels of eIF2α phosphorylation as compared to the 
neoplastic cells of non-responders [9]. These observations 
indicate that the clinically-relevant activation of the 
immune system results in the elimination of hyperploid 
cancer cells, which - conversely - can grow unrestrained 
in the absence of an adequate immune response. 
Our findings reveal an unsuspected mechanism 
of anticancer immunosurveillance whereby hyperploid 
malignant cells are recognized and eliminated by the 
immune system as they exposed increased amounts of 
CRT on their plasma membrane. Future work will have to 
establish whether is mechanism constitutes a meaningful 
target for the development of novel immunotherapeutic 
strategies against malignancy.
Laura Senovilla: INSERM, U848, Villejuif, France; Institut 
Gustave Roussy, Villejuif, France; Université Paris Sud/
Paris XI, Le Kremlin Bicêtre, France
Lorenzo Galluzzi: Institut Gustave Roussy, Villejuif, 
France; Université Paris Descartes/Paris V, Sorbonne 
Paris Cité, Paris, France
Guillermo Mariño: INSERM, U848, Villejuif, France; 
Institut Gustave Roussy, Villejuif, France; Université Paris 
Sud/Paris XI, Le Kremlin Bicêtre, France
Ilio Vitale: 1INSERM, U848, Villejuif, France; 2Institut 
Gustave Roussy, Villejuif, France; Université Paris Sud/
Paris XI, Le Kremlin Bicêtre, France
Maria Castedo: INSERM, U848, Villejuif, France; Institut 
Gustave Roussy, Villejuif, France; Université Paris Sud/
Paris XI, Le Kremlin Bicêtre, France
Guido Kroemer: INSERM, U848, Villejuif, France; 
Université Paris Descartes/Paris V, Sorbonne Paris 
Cité, Paris, France; Metabolomics Platform, Institut 
Gustave Roussy, Villejuif, France; Centre de Recherche 
des Cordeliers, Paris, France; Pôle de Biologie, Hôpital 
Européen Georges Pompidou, AP-HP, Paris, France
Correspondence: Guido Kroemer, email kroemer@orange.fr 
Correspondence: Maria Castedo, email castedo@igr.fr 
Received: November 12, 2012;
Published: November 20, 2012;
REFERENCES
1. Hanahan D, Weinberg RA. Cell. 2011; 144:646-74.
2. Negrini S et al. Nat Rev Mol Cell Biol. 2010; 11:220-8.
3. Gordon DJ et al. Nat Rev Genet. 2012; 13:189-203.
4. Vitale I et al. Nat Rev Mol Cell Biol. 2011; 12:385-92.
5. Matzinger P. Annu Rev Immunol. 1994; 12:991-1045.
6. Finn OJ. Ann Oncol. 2012; 23 Suppl 8:viii6-9.
7. Raulet DH, Guerra N. Nat Rev Immunol. 2009; 9:568-80.
8. Kroemer G  et al. Annu Rev Immunol. 2013; 31: In press.
9. Senovilla L et al. Science. 2012; 337:1678-84.
10. Senovilla L et al. Oncoimmunology. 2012; 1: In press.
Figure 1: Mechanisms of cancer cell recognition by the immune system. There are at least four distinct mechanisms whereby 
the immune system can detect - and potentially eliminate - (pre-)neoplastic cells. First, cancer cells often express tumor-associated 
antigens (TAAs) that - at least theoretically - can elicit anticancer immune responses. Second, (pre-)malignant cells often express increased 
amount of natural killer (NK)-cell activating receptor ligands (e.g., NKG2DL1) on their surface, hence promoting the activation of innate 
immunosurveillance mechanisms. Third, some antineoplastic agents, including anthracyclines and oxaliplatin, are capable of eliciting 
immunogenic cell death (ICD), ultimately leading to the activation of cognate tumor-specific immune responses. Forth, the immune system 
can detect cancer-associated hyperploidy, owing to a constitutively increased exposure of the endoplasmic reticulum (ER)-sessile protein 
calreticulin (CRT) on the plasma membrane of hyperploid tumor cells.
